<DOC>
	<DOC>NCT02645747</DOC>
	<brief_summary>The objective of this retrospective chart review is to evaluate drug utilization, usage patterns and indication of effectiveness Eylea in the routine clinical (real-life) management of patients who suffer from ME(Macular Edema), secondary to CRVO(Central Retinal Vein Occlusion ), and who started treatment with Eylea for this indication.</brief_summary>
	<brief_title>Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<criteria>Male or female adult patients who suffer from visual impairment due to ME secondary to CRVO AntiVEGF treatmentnaive patients who started reimbursed Eylea treatment between the 1st of June 2014 and the 28th of February 2015 Patients diagnosed with neovascular glaucoma secondary to CRVO will be excluded.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>